AIM2 and Cowden disease: By demonstrating IMP’s efficacy in targeting this pathway—evidenced by reduced AIM2 expression, diminished pyroptosis, and attenuated fibrosis across human, murine, and cellular models—our study nominates AIM2 inhibition as a viable strategy for treating CD-associated intestinal fibrosis.